Aethlon Medical (AEMD) announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group to act as the company’s exclusive financial advisor in connection with this process. The company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities. Maxim will assist the company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEMD:
- Aethlon Medical Shareholders Approve Share Expansion and Governance
- Aethlon Earnings Call Balances Trial Progress With Cash Risk
- Aethlon Medical Posts Q3 Results, Highlights Hemopurifier Progress
- Aethlon Medical reports Q3 EPS ($2.45) vs. ($10.05) last year
- AEMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?